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Abstract  
Introduction: Human leukocyte antigen-G (HLA-G) is a non-classical HLA class I molecule that 
differs from classical HLA class I molecules for low allelic polymorphism and restricted tissue 
distribution. In physiological conditions HLA-G molecules are expressed on trophoblast at the fetal-
maternal interface and other sites of immune privilege, such as thymus and cornea, where have an 
important role in the maintenance of a tolerogenic condition. In fact, HLA-G regulates the immune 
response through its immune-modulatory and anti-inflammatory function on both innate and 
adaptive immunity. HLA-G molecules are expressed as membrane bound and soluble isoforms 
(mHLA-G, sHLA-G) that bind and activate immune-inhibitory receptors (ILT2, ILT4, KIR2DL4) 
expressed on immune cells. Recently, HLA-G molecule has been shown to have an important 
implication in different pathological situations, such as infections and autoimmune diseases, where 
HLA-G shows aberrant expression and specific HLA-G gene polymorphisms correlate with disease 
severity and outcome. Moreover, HLA-G could be up-modulated and used as a immune-escape 
mechanism by virus and tumours. On the basis of this knowledge, HLA-G may exhibit two distinct 
effects in pathological conditions: it could be protective in Th1-based inflammatory and 
autoimmune diseases or it could be detrimental in tumors or infectious diseases. The aim of this 
thesis is to investigate the role of HLA-G mlecules in different pathological conditions: microbial 
infections and autoimmune diseases.  
Material and methods: The data herein reported were achieved using different molecular, 
proteomic and cellular techniques. The most important are the following: soluble (s)HLA-G was 
analysed by ELISA assay and Western Blot analysis; HLA-G gene polymorphism and mRNA were 
analysed by PCR, RT-PCR and RealTime PCR; membrane-bound (m)HLA-G was investigate using 
flow cytometry and immunofluorescence; to perform in vitro studies both continuous and primary 
cell lines culture were used. 
Results: The role of HLA-G was determined during microbial infections [(1) viral and (2) bacterial] 
and autoimmune diseases [3].  
1) HLA-G in viral infections. I focused my research on three viruses : HPV, HBV and hCMV.  
Firstly, I focused on the role of HLA-G polymorphisms in HPV and HBV infection susceptibility. 
We identify that two polymorphisms in the 3’ untranslated region of the HLA-G gene (3’ UTR) (14 
bp ins/del, +3142C>G) are involved in susceptibility to HPV infection. Indeed, we reported that the 
14 bp del allele is associated with a high risk of HPV infection, and the del/C haplotype facilitates 
   
 
the development of invasive cervical cancer. By literature it is known that HLA-G is implicated in 
chronic hepatits B pathogenesis. Our study evidenced the importance of 14 bp ins/del 
polymorphism influence also concerning HBV infection, revealing an association between the 14 
bp ins/del polymorphism and an enhanced HBV activity in presence of high HBV DNA levels. 
Again, the analysis of the correlation between HLA-G and primary hCMV infection during 
pregnancy reported a strong correlation between sHLA-G amount found in maternal plasma and in 
the amniotic fluids and the symptomatology in the hCMV infected foetuses. 
Last, the ability of inducing HLA-G was found also in HPV positive Sinonasal polyposis (SNP), a 
chronic inflammatory pathology that could develop after HPV infection. Our data showed that 
epithelial cells from nasal polyps obtained from HPV-11 positive SNP patients presented the 
expression of mHLA-G and IL-10R and secretion of sHLA-G and IL-10 in culture supernatants, 
while no HLA-G expression was observed in HPV negative polyps.  
2) HLA-G in bacterial infections. I investigate the role of HLA-G during P.aeruginosa infection.  
First of all, I analysed HLA-G modulation in patients affected by Cystic Fibrosis (CF) .  
We found lower HLA-G levels in plasma of CF patients that, after treatment, became 
undistinguishable from those found in CTRLs. HLA-G was higher in the exhaled breath 
condensate (EBC) of CF patients and was normalized after antibiotic therapy only in CF patients 
that were free of P. aeruginosa infection. Thus, HLA-G levels correlate with the efficacy of 
antibiotic treatment and the higher HLA-G expression observed in the CF lung microenvironment 
is associated with P. aeruginosa infection, suggesting that this molecule could play a role in 
bacterial immune-escape mechanisms. Furthermore, we identify that a specific soluble molecules 
of P.aeruginosa Quorum Sensign (QS), 3-o-C12-HSL, is able to induce HLA-G expression 
particularly in monocyte U937 and Jurkat T cell lines through the CREB\p38 phosphorylation. 
3) HLA-G in autoimmune and inflammatory diseases. I investigated HLA-G in different 
pathologies characterized by a dysregulation in host immune system in which HLA-G plays a 
central role: rheumatoid arthritis, Multiple sclerosis, Crohn’s disease and psoriasis.  
In all this conditions we identify a strong correlation between HLA-G 14bp INS/DEL and 
+3142C>G polymorphisms and soluble protein levels. In particular, early rheumatoid arthritis 
(ERA) treated patients with low sHLA-G and membrane HLA-G expression suffered a more severe 
disease while those with a significantly improved disease status were characterized by the presence 
of the DEL allele and higher HLA-G expression that correlates with lower DAS28 scores. 
   
 
Concerning Multiple Sclerosis, serum and CSF sHLA-G levels were more elevated in high 
producers MS patients with C/C,DEL/DEL HLA-G genotype. Our group also reported higher 
frequency of HLA-G dimers in relapse-remitting (RRMS) patients that suggests their implication in 
reducing the inflammatory status in MS. The implications of HLA-G polymorphisms and protein 
expression in autoimmunity was also confirmed in psoriasis, where we found an increase in HLA-
G plasmatic levels of systemic treated patients and a significant association between HLA-
G14bpDEL allele and 14bpDEL/DEL genotype with acitretin clinical outcome, and in Crohn’s 
Disease (CD), in which we reported that the 14-bp Del/Ins polymorphism of HLA-G gene and the 
presence of dimers are associated with the risk of CD and suggest a role for sHLA-G as prognostic 
marker for progressive disease. 
Conclusion: The implication of HLA-G proteins in creating an impaired immune response during 
autoimmunity and microbial infections has been here confirmed. It appears even more evident that 
understanding the functions of HLA-G molecules in these disorders could help in the identification 
of new approaches to control HLA-G production. Moreover,  HLA-G could fulfil the necessity of 
an easy and fast identification biomarker for disease diagnosis and prevention. HLA-G could 
represent a concrete help in disease outcome prediction and in supporting treatment decisions in 
different pathological conditions, such as infection and autoimmune diseases. 
 
 
 
